Understanding the market, your competitors and your audience is a great start but there is more to forecasting for pharma companies than that. Forecasting requires input from multiple sources that are constantly evolving – every FDA decision, clinical trial setback (yours or someone else’s), IPO, merger and funding round influences the future of the industry and effective forecasting needs to account for that.
Consensus Pharma forecasting is one proven approach to managing the complex, interconnected nature of the market. While forecasts from individual brokers are useful, bringing together thousands of forecasts helps provide a more balanced view. Evaluate Pharma provides users with 12,500 consensus forecasts to 2028, and the most comprehensive coverage of drug sales at an indication level with 6,000 worldwide and US consensus forecasts. Our unique historical archive spans 1.5m+ consensus forecasts of 10,000 products dating back to 2003.